Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease

[1]  K. Weinfurt,et al.  The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  F. Saad,et al.  Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. , 2005, Journal of the National Cancer Institute.

[3]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[4]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[5]  C. Pashos,et al.  Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy , 2004, Cancer.

[6]  Shelby D Reed,et al.  Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. , 2004, The Journal of urology.

[7]  Matthew R. Smith.  Management of treatment-related osteoporosis in men with prostate cancer. , 2003, Cancer treatment reviews.

[8]  P. Kantoff,et al.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. U. Uyl‐de Groot,et al.  Costs of prostate cancer, metastatic to the bone, in the Netherlands. , 2003, European urology.

[10]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[11]  Kevin Regan,et al.  Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Dogliotti,et al.  Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases. , 2002, The International journal of biological markers.

[13]  M. Resnick,et al.  Skeletal fractures negatively correlate with overall survival in men with prostate cancer. , 2002, The Journal of urology.

[14]  G. Mundy.  Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.

[15]  R. DiPaola,et al.  State-of-the-art treatment of metastatic hormone-refractory prostate cancer. , 2002, The oncologist.

[16]  F. Saad,et al.  The New Bisphosphonate, Zometa® (Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate , 2002, Cancer investigation.

[17]  C. Catton,et al.  A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma , 2001, Cancer.

[18]  L. Dogliotti,et al.  Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. , 2000, The Journal of urology.

[19]  D. Ferguson,et al.  Progressive osteoporosis during androgen deprivation therapy for prostate cancer. , 2000, The Journal of urology.

[20]  R. De Angelis,et al.  Estimating Relative Survival of Italian Cancer Patients from Sparse Cancer Registries Data , 1997, Tumori.